Back to the Future: Reexamining Treatment in RA
On-demand Audio Podcast
Jointly sponsored by North American Center for Continuing Medical Education, LLC, and the University of Cincinnati
Faculty
Marc D. Cohen, MD
Professor of Medicine
National Jewish Medical and Research Center
Denver, Colorado
Joseph A. Markenson, MD
Professor of Clinical Medicine
Weill Medical College of Cornell University
Hospital for Special Surgery
New York, New York
Target Audience
This activity is designed for rheumatologists and other healthcare professionals who manage the treatment of patients with rheumatoid arthritis (RA).
Learning Objectives
After completing this activity, participants should be able to:
- Interpret new safety and efficacy data, including those presented at ACR/ARHP, on combination therapy, triple DMARD therapy, and biologic switching
- Evaluate the current ACR/EULAR diagnostic and treatment criteria and their impact on the management of RA patients
- Explain how clinical measurement tools have been used to achieve tight RA control and summarize how these tools can be used in clinical practice to optimize patient care
Activity Overview
This on-demand podcast is available in audio with the presentation manuscript.
To be eligible for documentation of credit, participants must participate in the full activity, complete the 5-question post test with a score of 80% or better, and complete the evaluation form. After successful completion of the post test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.
There is no fee associated with this activity.
Release Date: March 31, 2010
Expiration Date: March 31, 2011
Estimated time to complete: 15 minutes
For questions regarding this activity, please call 609-371-1137
Hardware/Software Requirements
All educational activities are accessible via a computer with 650 MHz PC, 128 MB RAM, Windows or MAC operating system, Internet Explorer, Netscape, or Safari browsers. Windows Media Player, sound card, and speakers are required for streamed audio. Flash Player, sound card, and speakers are required for video programs. A pdf reader is required for print publications. Please direct technical questions to webmaster@naccme.com.
CME Accreditation
The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Cincinnati designates this educational activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Independent Clinical Reviewer: Mandana Hashefi, MD, FACR, Medical Faculty Associates, Division of Rheumatology, George Washington University, Washington, DC
Planning Committee
The planning committee comprises Marc D. Cohen, MD, Jospeh A. Markenson, MD, and Mandana Hashefi, MD; Kay Weigand, University of Cincinnati; and William Kormos, Emilie McCardell, Randy Robbin, and John Savage, NACCME.
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Cohen: Consultant—Genentech Inc, GSK, Human Genome Sciences, UCB
Dr. Markenson: Grant/Research Support—Abbott Laboratories, Genentech Inc; Consultant—Amgen Inc, Bristol-Myers Squibb Company, Pfizer Inc, UCB; Scientific Advisor—Amgen Inc, Pfizer Inc; Promotional Speakers’ Bureau—Abbott Laboratories, Amgen Inc, Bristol-Myers Squibb Company, Genentech Inc, Pfizer Inc, UCB
Dr. Hashefi: Has disclosed no relevant financial relationships with any commercial interests.
Ms. Weigand, Mr. Kormos, Ms. McCardell, Mr. Robbin, and Mr. Savage, and have reported no relevant financial relationships with any commercial interests.
NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentation.
The faculty has disclosed that no off-label/unapproved use(s) of drugs and/or devices will be discussed.
Privacy Policy
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate reporting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2010 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.
Grant Support
Supported by educational grants from Genentech Inc and Biogen Idec Inc, Bristol-Myers Squibb Company, Centocor Ortho Biotech Inc, and Abbott Laboratories.
